Global demand for drugs is growing faster than GDP growth, at a rate twice as fast until 2000. While growth is expected to moderate, it should remain permanently higher than that of GDP. Maintain or develop a competitive drug industry is therefore a favorable factor to overall economic growth and employment.
Most of the research, development and production of drugs in France are made of French companies, including the top five national players: Sanofi, Servier, Ipsen, Pierre Fabre and LFB. By themselves, these five groups represent over 45% of this sector's workforce, almost 60% of R&D investment and more than half of the researcher workforce. France also has a whole network of companies which cover all the value chain of the drug development(research, development, production, marketing) that are carriers of innovations.